AONC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AONC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
American Oncology Network's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $12 Mil. American Oncology Network's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $131 Mil. American Oncology Network's annualized EBITDA for the quarter that ended in Sep. 2024 was $20 Mil. American Oncology Network's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was 7.27.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for American Oncology Network's Debt-to-EBITDA or its related term are showing as below:
During the past 4 years, the highest Debt-to-EBITDA Ratio of American Oncology Network was 8.11. The lowest was -6.04. And the median was 5.51.
The historical data trend for American Oncology Network's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
American Oncology Network Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Debt-to-EBITDA | - | 8.11 | 5.51 | -3.26 |
American Oncology Network Quarterly Data | |||||||||||
Dec20 | Dec21 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Debt-to-EBITDA | Get a 7-Day Free Trial | -1.40 | -1.98 | -2.03 | 11.35 | 7.27 |
For the Medical Care Facilities subindustry, American Oncology Network's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Healthcare Providers & Services industry and Healthcare sector, American Oncology Network's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where American Oncology Network's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
American Oncology Network's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (7.881 | + | 120.444) | / | -39.351 | |
= | -3.26 |
American Oncology Network's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (12.388 | + | 131.314) | / | 19.772 | |
= | 7.27 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.
American Oncology Network (OTCPK:AONC) Debt-to-EBITDA Explanation
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
Be Aware
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of American Oncology Network's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Stephen Divers | director, officer: Chief Medical Officer | 133 HARMONY PARK CIRCLE, HOT SPRINGS AZ 71913 |
Todd Schonherz | director, officer: Chief Executive Officer | 14543 GLOBAL PARKWAY, 2ND FLOOR, FORT MEYERS FL 33913 |
Saba Capital Management, L.p. | 10 percent owner | 405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174 |
Boaz Weinstein | 10 percent owner | 405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174 |
David H Gould | officer: Chief Financial Officer | 7370 COLLEGE PARKWAY, SUITE 207, FORT MEYERS FL 33907 |
Erica Mallon | officer: General Counsel | 14543 GLOBAL PARKWAY, SUITE 110, FORT MEYERS FL 33913 |
Shalin Shah | director | 3402 W DR. MARTIN LUTHER KING JR. BLVD, TAMPA FL 33607 |
Vipul M Patel | director | 11704 SE 15TH CIRCLE, OCALA FL 34480 |
Vance Wright-browne | director | 22395 EDGEWATER DRIVE, PORT CHARLOTTE FL 33980 |
James Stith | director | ONE LETTERMAN DRIVE, CM200, SAN FRANCISCO CA 94129 |
Aea Growth Equity Fund Lp | 10 percent owner | 520 MADISON AVE, 40TH FLOOR, NEW YORK NY 10022 |
Aea Growth Equity Fund (parallel) Lp | 10 percent owner | 520 MADISON AVE, 40TH FLOOR, NEW YORK NY 10022 |
Ravi Yang Sarin | director | C/O ARES MANAGEMENT LLC, 2000 AVENUE OF THE STARS, 12TH FLOOR, LOS ANGELES CA 90067 |
Brian R Hoesterey | 10 percent owner | C/O AEA INVESTORS LP, 666 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10103 |
Kevin Nazemi | director, officer: Chief Executive Officer | 10485 NE 6TH ST, UNIT 3930, BELLEVUE WA 98004 |
From GuruFocus
By Marketwired • 05-14-2024
By Marketwired • 09-27-2023
By Marketwired • 10-25-2023
By Marketwired • 05-15-2024
By Marketwired • 06-04-2024
By Marketwired • 04-30-2024
By GlobeNewswire • 05-03-2024
By Marketwired • 09-20-2023
By Marketwired • 06-03-2024
By Marketwired • 05-16-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.